Boehringer, Lilly start acute heart failure trial with JardianceBoehringer and Eli Lilly have started a large-scale trial of their diabetes drug Jardiance in acute heart failure, Share XBoehringer, Lilly start acute heart failure trial with Jardiancehttps://pharmaphorum.com/news/boehringer-lilly-start-acute-heart-failure-trial-with-jardiance/
Solid Bio hit as FDA slaps clinical hold on DMD gene therapyThe FDA has placed another clinical hold on a gene therapy for Duchenne muscular dystrophy developed by Solid Share XSolid Bio hit as FDA slaps clinical hold on DMD gene therapyhttps://pharmaphorum.com/news/solid-bio-hit-as-fda-slaps-clinical-hold-on-dmd-gene-therapy/
Genfit announces data from algorithm-based NASH testThe pharma company Genfit has announced supportive data from a study involving a non-invasive algorithm driven blood test Share XGenfit announces data from algorithm-based NASH testhttps://pharmaphorum.com/news/genfit-announces-data-from-potential-nash-blood-test/
UK should pay $25 million for ‘Netflix’ antibiotic subscriptionAn expert has said the UK must pay upwards of $25 million per year to drug companies developing Share XUK should pay $25 million for ‘Netflix’ antibiotic subscriptionhttps://pharmaphorum.com/news/uk-should-pay-at-least-25-million-for-netflix-antibiotic-subscription-says-expert/
FDA decision on Opdivo/Yervoy in liver cancer due next MarchThe FDA has started a priority review of Bristol-Myers Squibb’s immuno-oncology combination of Opdivo and Yervoy in liver Share XFDA decision on Opdivo/Yervoy in liver cancer due next Marchhttps://pharmaphorum.com/news/fda-decision-on-opdivo-yervoy-in-liver-cancer-due-next-march/
AZ fleshes out positive trial of revitalised lupus drug anifrolumabAfter being all-but written off a year ago, AstraZeneca’s anifrolumab has been reborn with new data that suggest Share XAZ fleshes out positive trial of revitalised lupus drug anifrolumabhttps://pharmaphorum.com/news/az-fleshes-out-positive-trial-of-revitalised-lupus-drug-anifrolumab/
GSK must continue to improve R&D, says CEO WalmsleyIt’s been two and a half years since Emma Walmsley took over as CEO of GlaxoSmithKline, and at Share XGSK must continue to improve R&D, says CEO Walmsleyhttps://pharmaphorum.com/news/gsk-must-continue-to-improve-rd-says-ceo-walmsley/
Labour peer says he opposes Corbyn-style state-funded drugs firmA Labour peer has spoken out against the idea of a nationalised drugs industry, saying that proposals for Share XLabour peer says he opposes Corbyn-style state-funded drugs firmhttps://pharmaphorum.com/news/labour-peer-corbyn-state-funded-drugs/
Celgene scores FDA okay for thalassaemia drug ReblozylThe FDA has approved Celgene and Acceleron’s Reblozyl, which is the first drug to be approved in the Share XCelgene scores FDA okay for thalassaemia drug Reblozylhttps://pharmaphorum.com/news/celgene-scores-fda-okay-for-thalassaemia-drug-reblozyl/
CVS rolls out digital messaging for meds adherence after pilotUS pharmacy chain CVS Specialty has made its two-way messaging app available to 80% of eligible patients on Share XCVS rolls out digital messaging for meds adherence after pilothttps://pharmaphorum.com/news/cvs-rolls-out-digital-messaging-for-meds-adherence-after-pilot/
Sandoz buys Aspen’s Japanese generics business for up to $434 millionNovartis’ biosimilars and generics division Sandoz has agreed to buy the Japanese business of the global generics firm Share XSandoz buys Aspen’s Japanese generics business for up to $434 millionhttps://pharmaphorum.com/news/sandoz-buys-aspens-japanese-generics-business-for-up-to-434-million/
FDA tags F2G’s olorofim as Breakthrough Therapy for fungal infectionsThe US drugs regulator has tagged F2G’s olorofim as a potential Breakthrough Therapy for life-threatening fungal infections, pledging Share XFDA tags F2G’s olorofim as Breakthrough Therapy for fungal infectionshttps://pharmaphorum.com/news/fda-tags-f2gs-olorofilm-as-breakthrough-therapy-for-mould-infections/
NICE backs NHS funding for two cannabis-based drugs for first timeNICE has recommended two of GW Pharma’s cannabis-based medicines, the first time that medicines derived from the plant Share XNICE backs NHS funding for two cannabis-based drugs for first timehttps://pharmaphorum.com/news/nice-includes-bayer-gws-cannabis-based-sativex-in-ms-guideline-for-first-time/
AZ preps for US filing of kidney disease anaemia drugAstraZeneca is gearing up for a US filing for its roxadustat, a potential drug for patients with anaemia Share XAZ preps for US filing of kidney disease anaemia drughttps://pharmaphorum.com/news/az-preps-for-us-filing-of-kidney-disease-anaemia-drugs/
Roche joins others in dropping myostatin inhibitor for DMDThe prospects of a new class of Duchenne muscular dystrophy therapies have taken another downturn after Roche abandoned Share XRoche joins others in dropping myostatin inhibitor for DMDhttps://pharmaphorum.com/news/roche-joins-others-in-dropping-myostatin-inhibitor-for-dmd/
Novo Nordisk buys rights to NASH drug from Japan’s UBENovo Nordisk has acquired rights to a preclinical drug that could be used to treat non-alcoholic steatohepatitis (NASH), Share XNovo Nordisk buys rights to NASH drug from Japan’s UBEhttps://pharmaphorum.com/news/novo-nordisk-buys-rights-to-nash-drug-as/
Pharma to increase spend on digital marketing – reportA third of pharma companies will be spending more than half of their marketing budget on digital channels Share XPharma to increase spend on digital marketing – reporthttps://pharmaphorum.com/news/pharma-to-increase-spend-on-digital-marketing-report/
First Rituxan biosimilar Truxima set to make its debut in USBiosimilar competition to Roche’s big-selling Rituxan has arrived in the US, with Teva gearing up to launch its Share XFirst Rituxan biosimilar Truxima set to make its debut in UShttps://pharmaphorum.com/news/first-rituxan-biosimilar-truxima-set-to-makes-its-debut-in-us/
The Application Of Machine Learning To Field Insights Share XThe Application Of Machine Learning To Field Insightshttps://pharmaphorum.com/partner-content/the-application-of-machine-learning-to-field-insights/
Formulation & Drug Delivery Series US Share XFormulation & Drug Delivery Series UShttps://pharmaphorum.com/partner-content/formulation-drug-delivery-series-us/
34th PM Society Awards – Tickets on sale! Share X34th PM Society Awards – Tickets on sale!https://pharmaphorum.com/partner-content/34th-pm-society-awards-tickets-on-sale/
The Gut Week Summit 2020 Share XThe Gut Week Summit 2020https://pharmaphorum.com/partner-content/the-gut-week-summit-2020/
Kristin Milburn joins Healthware Group as Global Head of Digital Health Partnerships Share XKristin Milburn joins Healthware Group as Global Head of Digital Health Partnershipshttps://pharmaphorum.com/partner-content/kristin-milburn-joins-healthware-group-as-global-head-of-digital-health-partnerships/
Hall & Partners appoints Stacy Vaughn to senior US health role Share XHall & Partners appoints Stacy Vaughn to senior US health rolehttps://pharmaphorum.com/news/hall-partners-stacy-vaughn-beth-stagg/
